DS-8201a Versus Ado Trastuzumab Emtansine for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Condition:   Breast Cancer Interventions:   Drug: Trastuzumab deruxtecan;   Drug: Ado-trastuzumab emtansine Sponsors:   Daiichi Sankyo, Inc.;   Daiichi Sankyo Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials